Skip to main content

Breckenridge gets FDA clearance for generic Exelon Patch

Levy

Breckenridge has received the Food and Drug Administration’s green light for rivastigmine transdermal system in dosage strengths of 4.6mg/24 hours, 9.5mg/24 hours and 13.3mg/24 hours.

The product is the generic of Novartis’ Exelon Patch. 

Breckenridge's product was developed in collaboration with Welding GMBH & Co. KG and SK Chemicals. 

The Exelon Patch and its generics had a market value of $161 million during the 12 months ended Sept. 30, 2019, according to industry sales data.

Breckenridge plans to launch the product immediately.

 

X
This ad will auto-close in 10 seconds